Skip to main content

COVID-19 Advisory: Visitor restrictions are in place for all Phoenix Children’s locations. Masks are required for all visitors and for patients ages 2+. For more information, visit our COVID-19 Resource Center.

Michael M. Henry, MD

Edit Profile

Michael M. Henry, MD

Edit Profile

Specialty

Areas of Expertise

  • Pediatric Oncology Pediatric Hematology Non-Hodgkin Lymphomas Liquid Tumors Hodgkin Lymphomas Histiocytosis Benign Blood Disorder

About Michael M. Henry, MD

As a pediatric hematologist/oncologist, Michael Henry, MD, specializes in treating blood cancers and other blood diseases.

Dr. Henry is a member of the Phoenix Children's Liquid Tumor Team in the Center for Cancer and Blood Disorders. He focuses on histiocytic disorders as the director of the Histiocytosis Program and also treats leukemia and lymphoma. Dr. Henry serves as the institutional principal investigator for several clinical trials for these conditions, and he strives to use the most advanced treatments available.

Dr. Henry enjoys working with children and their families. The idea of guiding them through the difficult journey of a cancer diagnosis and the treatment process is what led Dr. Henry to medicine. He chose Phoenix Children's to be a part of the hospital's tremendous growth. The hospital had the perfect role for him, and "I've never looked back," Dr. Henry says.

...Read more

As a pediatric hematologist/oncologist, Michael Henry, MD, specializes in treating blood cancers and other blood diseases.

Dr. Henry is a member of the Phoenix Children's Liquid Tumor Team in the Center for Cancer and Blood Disorders. He focuses on histiocytic disorders as the director of the Histiocytosis Program and also treats leukemia and lymphoma. Dr. Henry serves as the institutional principal investigator for several clinical trials for these conditions, and he strives to use the most advanced treatments available.

Dr. Henry enjoys working with children and their families. The idea of guiding them through the difficult journey of a cancer diagnosis and the treatment process is what led Dr. Henry to medicine. He chose Phoenix Children's to be a part of the hospital's tremendous growth. The hospital had the perfect role for him, and "I've never looked back," Dr. Henry says.

When he's not working, Dr. Henry enjoys composing and performing electronic music. He also enjoys learning website and iPhone app development.

Read less

+Education & Training

Board Certification

Pediatric Hematology/Oncology; General Pediatrics

Medical School / Education

Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA

Residency

(Pediatrics) Al Dupont Hospital of Children/Thomas Jefferson University Hospital, Wilmington, DE

Fellowship

(Hematology/Oncology) Children's National Medical Center, Washington, D.C.

+Academic and Professional Affiliations

Academic Affiliations

Assistant Professor of Clinical Pediatrics, Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona; Assistant Professor of Pediatrics, Department of Pediatrics, Mayo College Of Medicine, Rochester, Minnesota; Assistant Professor of Pediatrics, Department of Pediatrics, Creighton University School of Medicine, Phoenix, Arizona

Professional Affiliations

Children's Oncology Group, American Society of Pediatric Hematology/Oncology; Histiocyte Society

+Awards

  • Faculty Teacher of the Year (Phoenix Children's Hospital) 2005-2006

+Research & Publications

Padman R, Henry M. The use of BiPAP in the treatment of the acute chest syndrome of sickle cell disease. Delaware Medical Journal. 76(5):119-203 (2004).

Henry M, Driscoll C, Miller M, Chang T, Minniti C. Pseudo tumor cerebri in children with sickle cell disease: A case series. Pediatrics113(3):e265-e269 (2004).

Mitchell S A, Brown K B, Henry M M, Mintz M, Catchpoole D, LaFleur B,Stephan D A.Inter- Platform comparability of micro arrays in acute lymphoblastic leukemia. BMC Genomics
5:71-77(2004).

Mintz M B, Sowers R, Brown K M, Hilmer S C, Mazza B, Huvos A G, Meyers P A, Lafleur B, McDonough W S, Henry M M, Ramsey K E, Antonescu C R, Chen W, Healey J H, Daluski A, Berens M E, Macdonald T J, Gorlick R, Stephan D A. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Research 65(5):1748-54(2005).

Harris R E, Termuhlen A M, SmithLM, Lynch J, Henry M M, Perkins S L, Gross T G, Warkentin P, Vlachos A, Harrison L, Cairo M S. Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A 5962. Blood and Bone Marrow Transplantation. Feb;17(2):249-58 (2011).

Kasem A J, Bulloch B, Henry M, M D, ShahK ,Dalton H. Procalciton in asa marker of bacteremia in children with fever and a central venous catheter presenting to the Emergency Department. Pediatric Emergency Care 28(10):1-5(2012).

Johnson K, Notrica D M, Carpentieri D, Jaroszewski D, Henry M M. Successful treatment of recurrent pediatric inflammatory myofibroblastictumor in a single patient with a novel chemotherapeutic regimen containing celecoxib. J Pediatr Hematol Oncol Jul; 35(5):414-6 (2013).

Chellapandian D, Das R, Zelley K, Wiener S J, Zhao H, Teachey D T, Nichols K E; EBV-HLH Rituximab Study Group. Treatment of Epstein Barr virus- induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeuticregimens. Br J Haematol Aug; 162(3):376-82(2013).

Abstracts

2009
Barrett D, Wey P ,Henry M, Pasztor L ,Dickman P, DeMello D. Blastic plasma cytoiddendritic cell leukemiaina child; case report and literature review. Poster presentation, XXII International Symposiumon Technological Innovations in Laboratory Hematology, Las Vegas,NV.

2010
Nelmes, Guo D, O'Sullivan M, Henry M, Fong A, Kiiveri H, Stone G, Kadupitige SR, Gaeta B, Bain M, Dahl N, Schuster J, Catch poole DR. Increased ribosomal protein L38 expression is indicativeof CD34+ cells present in childhood acute lymphoblastic leukaemia. Poster presentation, Lorne Cancer Conference, PhillipIsland, Victoria, Australia.

2011
Henry M, Dickman P.The expression of COX-2 in Langerhans Cell Histiocytosis. Poster presentation, The 27th Meeting of the Histiocyte Society (Vienna, Austria), October 2011

2011
Henry M. Hematophago cytic lymphohistiocytosis in the Native American Population- Experience at Phoenix Children's Hospital. Poster presentation, The 27th Meeting of the Histiocyte Society(Vienna, Austria), October 2011.

2014
Tomboc P, Henry M. Time to Antibiotic Administration for Febrile, Neutropenic Patients is Significantly Reduced by Using a Clinical Pathway in the Emergency Department. Poster Presentation, 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Chicago, IL.

Lymphoma/Leukemia; Lymphoproliferative Disease; Histiocytic Disorders; Benign Hematology; Technology in the Workplace<br/>
Share this page